166 related articles for article (PubMed ID: 35349227)
21. Efficacy and safety of immune checkpoint inhibitors in elderly patients (≥70 years) with squamous cell carcinoma of the head and neck.
Saleh K; Auperin A; Martin N; Borcoman E; Torossian N; Iacob M; Ferrand FR; Khalife N; Baste N; Guigay J; Le Tourneau C; Daste A; Saada-Bouzid E; Even C
Eur J Cancer; 2021 Nov; 157():190-197. PubMed ID: 34536943
[TBL] [Abstract][Full Text] [Related]
22. Exploring long-term responses to immune checkpoint inhibitors in recurrent and metastatic head and neck squamous cell carcinoma.
Bila M; Franken A; Van Dessel J; Garip M; Meulemans J; Willaert R; Hoeben A; Vander Poorten V; Clement PM
Oral Oncol; 2024 Feb; 149():106664. PubMed ID: 38113661
[TBL] [Abstract][Full Text] [Related]
23. The predictive and prognostic value of weight loss and body composition prior to and during immune checkpoint inhibition in recurrent or metastatic head and neck cancer patients.
Willemsen ACH; De Moor N; Van Dessel J; Baijens LWJ; Bila M; Hauben E; van den Hout MFCM; Vander Poorten V; Hoeben A; Clement PM; Schols AMWJ
Cancer Med; 2023 Apr; 12(7):7699-7712. PubMed ID: 36484469
[TBL] [Abstract][Full Text] [Related]
24. Immune-Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer With Uncommon Histology.
Manglaviti S; Brambilla M; Signorelli D; Ferrara R; Lo Russo G; Proto C; Galli G; De Toma A; Occhipinti M; Viscardi G; Beninato T; Zattarin E; Bini M; Lobefaro R; Massa G; Bottiglieri A; Apollonio G; Sottotetti E; Di Mauro RM; Trevisan B; Ganzinelli M; Fabbri A; de Braud FGM; Garassino MC; Prelaj A
Clin Lung Cancer; 2022 Jan; 23(1):e17-e28. PubMed ID: 34334296
[TBL] [Abstract][Full Text] [Related]
25. Are immune checkpoint inhibitors ineffective in treating patients with head and neck squamous cell carcinoma aged 75 years or Older? A Meta-Analysis.
Zhang S; Zheng M; Tian H; Liu W; Feng Z; Xing S; Han F
Oral Oncol; 2024 Jan; 148():106632. PubMed ID: 38039875
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of Chemotherapy After Immune Checkpoint Inhibitor Discontinuation in Head and Neck Cancer.
Fukuoka O; Saito Y; Mukai T; Hayashi T; Yamamura K; Sakai T; Kobayashi K; Akashi K; Yoshida M; Ando M; Yamasoba T
Laryngoscope; 2024 Jan; 134(1):228-235. PubMed ID: 37377185
[TBL] [Abstract][Full Text] [Related]
27. Chemotherapy after immune checkpoint blockade in patients with recurrent, metastatic squamous cell carcinoma of the head and neck.
Kacew AJ; Harris EJ; Lorch JH; Schoenfeld JD; Margalit DN; Kass JI; Tishler RB; Haddad RI; Hanna GJ
Oral Oncol; 2020 Jun; 105():104676. PubMed ID: 32251982
[TBL] [Abstract][Full Text] [Related]
28. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
[TBL] [Abstract][Full Text] [Related]
29. Both combined or sequential use with immune checkpoint inhibitors on cetuximab-treated patients with recurrent or metastatic head and neck squamous cell carcinoma improve the overall survival.
Lien MY; Wang TH; Hsieh CY; Tsai MH; Hua CH; Cheng FM; Chung WH; Tang CH; Chia-Hsun Hsieh J
Oral Oncol; 2021 Aug; 119():105380. PubMed ID: 34146822
[TBL] [Abstract][Full Text] [Related]
30. Treatment sequence of cetuximab and immune checkpoint inhibitor in head and neck squamous cell carcinoma differentially affects outcomes.
Park JC; Durbeck J; Clark JR; Faden DL
Oral Oncol; 2020 Dec; 111():105024. PubMed ID: 33065374
[TBL] [Abstract][Full Text] [Related]
31. Overall survival and PD-L1 expression in patients with recurrent or metastatic head and neck cancer treated with nivolumab.
Okamoto I; Sato H; Tsukahara K
Auris Nasus Larynx; 2020 Aug; 47(4):676-686. PubMed ID: 32439271
[TBL] [Abstract][Full Text] [Related]
32. Effectiveness and safety of weekly paclitaxel and cetuximab as a salvage chemotherapy following immune checkpoint inhibitors for recurrent or metastatic head and neck squamous cell carcinoma: A multicenter clinical study.
Wakasaki T; Manako T; Yasumatsu R; Hara H; Toh S; Masuda M; Yamauchi M; Kuratomi Y; Nishimura E; Takeuchi T; Matsuo M; Jiromaru R; Hashimoto K; Komune N; Nakagawa T
PLoS One; 2022; 17(7):e0271907. PubMed ID: 35901098
[TBL] [Abstract][Full Text] [Related]
33. The association between body mass index and efficacy of pembrolizumab as second-line therapy in patients with recurrent/metastatic head and neck squamous cell carcinoma.
Zhang X; Rui M; Lin C; Li Z; Wei D; Han R; Ju H; Ren G
Cancer Med; 2023 Feb; 12(3):2702-2712. PubMed ID: 35975731
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of cetuximab plus PD-1 inhibitor differs by HPV status in head and neck squamous cell carcinoma: a systematic review and meta-analysis.
Zhang S; Zheng M; Nie D; Xu L; Tian H; Wang M; Liu W; Feng Z; Han F
J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36253001
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of cetuximab-containing regimens in the treatment of recurrent/metastatic head and neck cancer after progression to immune checkpoint inhibitors.
Lai CL; Chen TH; Chang PM; Tai SK; Chu PY; Yang MH
J Chin Med Assoc; 2022 Jun; 85(6):687-692. PubMed ID: 35507025
[TBL] [Abstract][Full Text] [Related]
36. Prognostic Value of Inflammatory and Nutritional Biomarkers of Immune Checkpoint Inhibitor Treatment for Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck.
Sakai A; Iijima H; Ebisumoto K; Yamauchi M; Teramura T; Yamazaki A; Watanabe T; Inagi T; Maki D; Okami K
Cancers (Basel); 2023 Mar; 15(7):. PubMed ID: 37046684
[TBL] [Abstract][Full Text] [Related]
37. Prognostic significance of nutritional indices in patients with head and neck squamous cell carcinoma treated with immune checkpoint inhibitors.
Miyamoto N; Takenaka Y; Sudo T; Eguchi H; Tanaka H; Fukusumi T; Takemoto N; Suzuki M; Inohara H
Acta Otolaryngol; 2023 Oct; 143(10):925-930. PubMed ID: 38059478
[TBL] [Abstract][Full Text] [Related]
38. Hyperprogressive disease and its clinical impact in patients with recurrent and/or metastatic head and neck squamous cell carcinoma treated with immune-checkpoint inhibitors: Korean cancer study group HN 18-12.
Park JH; Chun SH; Lee YG; Chang H; Lee KW; Kim HR; Shin SH; An HJ; Lee KE; Hwang IG; Ahn MJ; Kim SB; Keam B
J Cancer Res Clin Oncol; 2020 Dec; 146(12):3359-3369. PubMed ID: 32671504
[TBL] [Abstract][Full Text] [Related]
39. Nonlinear association between body mass index and overall survival in advanced NSCLC patients treated with immune checkpoint blockade.
Jain A; Zhang S; Shanley RM; Fujioka N; Kratzke RA; Patel MR; Kulkarni AA
Cancer Immunol Immunother; 2023 May; 72(5):1225-1232. PubMed ID: 36383245
[TBL] [Abstract][Full Text] [Related]
40. Cetuximab combined with paclitaxel or paclitaxel alone for patients with recurrent or metastatic head and neck squamous cell carcinoma progressing after EXTREME.
Chevalier T; Daste A; Saada-Bouzid E; Loundou A; Peyraud F; Lambert T; Le Tourneau C; Peyrade F; Dupuis C; Alfonsi M; Fayette J; Reure J; Huguet F; Fakhry N; Toullec C; Salas S
Cancer Med; 2021 Jun; 10(12):3952-3963. PubMed ID: 34080776
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]